Ivhebex

Human Hepatitis B Immunoglobulin, the active ingredient in Ivhebex, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity for hepatitis B exposure and is used in post‑exposure prophylaxis, prevention of mother‑to‑child transmission, and high‑risk prophylaxis.

GNH USA supplies Ivhebex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ivhebex, a human hepatitis B immunoglobulin, acts within the antiviral immune pathway to prevent hepatitis B virus infection.

- Post‑exposure prophylaxis: provides immediate passive immunity to individuals exposed to hepatitis B virus. - Mother‑to‑child transmission prevention: reduces risk of vertical transmission when administered to pregnant women or newborns. - High‑risk prophylaxis: protects healthcare workers or others with significant exposure risk from acquiring hepatitis B infection.

Adverse reactions may occur following intravenous administration of Ivhebex.

Common Side Effects: - Fever - Chills - Headache - Nausea - Injection‑site erythema or discomfort - Fatigue

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Hemolysis - Acute renal dysfunction - Thrombosis or embolic events - Aseptic meningitis - Severe hypotension

Ivhebex should be used with careful clinical assessment and monitoring.

- Assess hepatitis B status: confirm need for passive immunization before administration. - Monitor for allergic reactions: observe patients for signs of anaphylaxis during and after infusion. - Evaluate renal function: consider dose adjustment or close monitoring in patients with renal impairment. - Avoid in individuals with known IgA deficiency: risk of severe hypersensitivity. - Use with caution in pregnancy: safety category unknown, weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ivhebex may interact with other biologic products and therapies.

Major Interactions (Avoid): - Concurrent IgA‑containing blood products: increased risk of severe allergic reactions. - Live vaccines: potential interference with vaccine efficacy. - Immunosuppressive agents: may diminish passive immunity effect.

Moderate Interactions (Monitor Closely): - Anticoagulants: possible alteration of clotting parameters. - Corticosteroids: may affect immune response to the immunoglobulin. - Non‑live vaccines: monitor serologic response after administration.